AHNAK2 Knockout HeLa Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population derived from the HeLa cell line, engineered for targeted disruption of the AHNAK2 gene. This loss-of-function model enables systematic investigation of AHNAK2-dependent cellular processes without clonal selection, maintaining population-level heterogeneity while abolishing functional protein expression. The polyclonal format provides a physiologically relevant system for studying gene function in a context that more closely mirrors heterogeneous tumor cell populations.
The HeLa host cell line is an immortalized human cervical adenocarcinoma cell line originally isolated from Henrietta Lacks. As a well-established model in cancer biology, HeLa cells exhibit robust proliferative capacity and are broadly utilized for dissecting molecular mechanisms underlying cervical cancer and other malignancies. Their epithelial origin and intrinsic signaling network make them particularly suitable for examining genes implicated in cell adhesion, migration, and metastatic progression.
AHNAK2 encodes a large scaffold protein that orchestrates multiprotein complexes at the plasma membrane and cytoskeleton. It directly interacts with alpha-actinin and the S100A10/annexin A2 complex to modulate cytoskeletal dynamics and focal adhesion turnover. Mechanistically, AHNAK2 functions as a signaling hub that enhances epithelial-mesenchymal transition (EMT) and cell migration by activating TGF-beta and Wnt/beta-catenin pathways. Upstream, AHNAK2 expression is induced by TGF-beta, EGF, and hypoxia, placing it within feedforward loops that amplify pro-invasive signals. Downstream, AHNAK2 promotes upregulation of Snail, vimentin, MMP9, and cyclin D1, while engaging receptor and effector components TGFBR, SMAD2/3, beta-catenin, and FAK to drive tumor progression.
In the HeLa cervical cancer model, AHNAK2 knockout provides a powerful tool to dissect its role in EMT and metastasis. Given that AHNAK2 is frequently overexpressed in cervical and other carcinomas and correlates with poor prognosis, its disruption in HeLa cells allows direct assessment of changes in migratory and invasive capacity, cell adhesion properties, and signaling rewiring. This model facilitates the study of context-specific dependencies and may reveal vulnerabilities exploitable for therapeutic intervention.
Researchers can employ this polyclonal knockout population in diverse assays, including wound healing and transwell migration/invasion assays to evaluate motility, immunofluorescence and co-immunoprecipitation to map protein interactions, and western blotting or RT-qPCR to quantify expression changes in EMT markers and pathway components. Phospho-signaling analyses can interrogate TGF-beta and Wnt pathway activation states. These cells are suitable for investigating cervical cancer progression, EMT regulation, and metastasis mechanisms. For further details or technical support, please contact Ascent Research.
